Diagnosing and managing perinatal cholestasis in preterm infants

Perinatal cholestasis in a newborn signals impaired bile formation or flow. The key clue is conjugated hyperbilirubinemia, or direct bilirubin that is inappropriately high, rather than the unconjugated jaundice common after preterm birth. It is a syndrome with many causes: biliary atresia, sepsis, parenteral nutrition injury, congenital infection and inherited liver disease may sit underneath it. Delayed recognition can lead to fat-soluble vitamin deficiency, worsening liver function and, for some conditions, irreversible loss of bile ducts.

Preterm infants are vulnerable because hepatic bile-acid transport is still immature, while neonatal intensive care can add intravenous lipid exposure, sepsis, haemolysis, necrotising enterocolitis or multiple medications. Cholestatic jaundice may emerge during the first weeks rather than after the traditional two-week point. A direct bilirubin above 1 mg/dL (17 µmol/L) is generally abnormal in a neonate; a value around or above 2 mg/dL (34 µmol/L), a rising direct fraction, pale stool or deteriorating feeding requires urgent same-day review. Local network criteria should determine final escalation thresholds.

The FAOPS 2020 congress site documents the planned 21st Congress of the Federation of Asian and Oceania Perinatal Societies in Tokyo, in conjunction with PREBIC AA 2020. Its scientific programme, speakers, abstracts and travel information captured the international interest in perinatal medicine. The meeting was cancelled in April 2020 because of COVID-19 and international travel disruption, yet the site remains a reminder that shared protocols matter when neonatal evidence changes quickly.

For Australian teams, diagnosis is a coordination problem as well as a test-ordering problem. Tertiary neonatal services in Sydney, Melbourne, Brisbane and Perth often manage complex cases, while babies born in regional, rural or remote locations may need retrieval before diagnosis is complete. Safe care therefore depends on early measurement, a clear escalation route and communication with families, not on waiting for a tertiary consultant to request the next test.

Recognise cholestasis before it progresses

Cholestasis should be considered whenever jaundice persists, becomes darker or changes in character. Pale, acholic or clay-coloured stool is particularly important; dark urine, an enlarging liver, poor feeding, vomiting, fever, lethargy, bleeding or increasing oxygen requirements suggest a serious process. Examine the abdomen, fontanelle, skin, eyes and stools, and measure the infant’s weight and oxygen saturation. A jaundiced baby who is unwell needs immediate review, irrespective of gestational age.

The history should cover the antenatal course, delivery, family history, medications, transfusions, infection exposures, feeding, stool colour and urine output. Record the exact day jaundice began and whether it has worsened since discharge. Postnatal events and exposures include parenteral nutrition, antibiotics, anticonvulsants and other potentially hepatotoxic medicines; sepsis, NEC and haemolysis are equally important. An antenatal history should also consider substance exposure without assuming it explains liver dysfunction. The neonatal outcomes review provides useful context for that broader assessment.

Immediate care protects the infant while the cause is investigated. Review haemodynamic stability, glucose, temperature, oxygenation and urine output; obtain blood cultures and give empiric antibiotics when sepsis is possible; and review whether any medicine or feed exposure can be safely paused. Local emergency and retrieval policies remain authoritative. Document a direct bilirubin, stool colour and disposition before transfer, not merely a total bilirubin.

Build a focused diagnostic pathway

Start with a bilirubin trend that distinguishes the direct and total fractions, then obtain ALT, AST, GGT, alkaline phosphatase, albumin, INR or prothrombin time, full blood count, reticulocytes, glucose and electrolytes. Alkaline phosphatase can be physiologically high in preterm infants because of bone sources, while GGT and transaminases vary with age and illness; no single liver enzyme establishes cholestasis. A falling total bilirubin does not necessarily indicate recovery if the direct fraction is rising. Normal or low conjugated bilirubin does not exclude advanced liver failure when synthetic function is poor.

Abdominal ultrasound with hepatic artery Doppler is the first-line imaging study. It may identify an enlarged liver, bile plugs, a choledochal cyst or absent or reduced gallbladder findings, but a reassuring scan does not exclude biliary atresia. Hepatobiliary scintigraphy with HIDA may assist in selected cases, and biopsy is reserved for diagnostically uncertain disease after specialist review. Meanwhile, use a targeted pathway to investigate blood group incompatibility and haemolysis, congenital infection and neonatal hepatitis, urine reducing substances, cystic fibrosis, alpha-1 antitrypsin deficiency, galactosemia, bile-acid transporter defects and PFIC3.

Patterns can guide sequence rather than delay action. Early severe cholestasis with pale stool deserves same-day surgical or hepatology input; isolated mild cholestasis during parenteral nutrition requires nutritional review and close trends; systemic illness suggests sepsis until disproved. Older conference resources, such as the IC2AR 2017 archive, can help clinicians trace international discussions, but current Australian neonatal and hepatology guidance should guide testing and treatment. Avoid undirected metabolic panels that obscure the urgent pathway or repeated ultrasound when the clinical picture points to rapid intervention.

Treat the cause while protecting nutrition

Treatment follows the cause, and time matters. Suspected biliary atresia requires immediate transfer to a paediatric hepatobiliary service, vitamin K and preparation for timely Kasai portoenterostomy; waiting for a complete diagnostic work-up can reduce surgical options. Infection needs prompt antimicrobial treatment, while metabolic disease requires withdrawal of the offending substrate and specialist diet. Cystic fibrosis, alpha-1 antitrypsin deficiency and bile-acid transporter disorders should be managed through their respective specialist centres rather than by empirical medication alone. Teams can use the ASAP Rescue resources for resuscitation refresher work alongside local emergency policy, but that training does not replace a cholestasis escalation pathway.

For parenteral nutrition-associated cholestasis, the aim is to improve bile flow and reduce avoidable liver exposure without abruptly stopping essential nutrition. Use the mother’s own milk when available, advance tolerated enteral feeds, avoid unnecessary energy loads and reassess lipid dose, infusion duration and overall PN exposure each day. Evidence for ursodeoxycholic acid is inconsistent. Fish-oil-containing intravenous lipids may be considered in selected cases, but neither should replace good neonatal nutrition. Availability within Australian hospital formularies differs, and these specialist products require neonatology, pharmacy and dietetic review.

Supportive treatment includes vitamin K, vitamin D and individualised replacement of vitamins A, E and K according to cholestasis severity, dietary intake and monitored levels. Maintain energy and protein intake, fluid balance and glucose control, and correct coagulopathy or metabolic complications. Track direct bilirubin, ALT, AST, GGT, INR, albumin, weight gain and stool colour at clinically appropriate intervals. Pruritus is uncommon in early infancy but needs treatment when present. Recurrent cholestasis warrants a structured handover to outpatient hepatology, dietetics and community nursing.

Provide coordinated care across Australia

Australian geography shapes the pathway. Major neonatal intensive care units in Sydney, Melbourne, Brisbane and Perth work with state neonatal retrieval services, which can arrange a cot, transport nurse and an accepting hospital before a definitive diagnosis is known. A preterm infant with pale stool and rising direct bilirubin should not wait for a routine transfer request to be completed. The referring team should send a bilirubin trend, medication and nutrition history, stool description, antenatal history and the reasons for concern.

Remote and regional care adds cultural as well as logistical complexity. Aboriginal and Torres Strait Islander families may live far from a tertiary unit, and delayed transfer can separate infants from families, breast milk and community supports. Use Aboriginal hospitals, Aboriginal Community Controlled Health Services and local maternal-child health teams where families wish, involve family members according to the family’s preferences, and combine teleconsultation with safe, planned transport. Family-centred practices such as skin-to-skin contact, supported breastfeeding and involving parents at the cotside should continue whenever clinical condition allows.

Discharge planning begins before the bilirubin improves. The family needs a written medicine and feeding plan, a named contact for jaundice or feeding concerns, and an accessible route to repeat blood tests. Medicare covers public inpatient neonatal care, while outpatient prescriptions and eligible specialist formulas may be PBS-listed; standard preterm formula is also bought through the Australian retail market, with product availability varying between states and hospitals. Social work, lactation support, Indigenous liaison and community follow-up should be arranged before discharge rather than after a readmission.

Build a local response pathway

A practical unit protocol should separate actions that must happen immediately from investigations that can be staged. The following comparison helps teams prioritise without turning a differential diagnosis into a long unmonitored checklist.

Review each case at least daily while the direct bilirubin or liver enzymes are changing. A senior neonatologist should own the initial pathway, with hepatology, genetics, metabolic medicine, radiology, pharmacy and dietetics involved according to the working diagnosis. Give families plain-language information about why prolonged jaundice needs investigation, and ensure every transfer and handover states the latest direct bilirubin, trend, stool colour, coagulation results and nutrition plan.

Act now by appointing a clinical lead in each neonatal unit, publishing a 24-hour conjugated bilirubin escalation pathway and linking it to the relevant state retrieval service. Audit every case for time to direct-bilirubin measurement, specialist review and definitive treatment, then share the findings with families and the wider perinatal network. Teams building education resources should use the congress material and linked specialist sources as the starting point for a current, Australia-specific guideline rather than relying on an unverified checklist.